0.39% -0.015

Alvotech (ALVO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Alvotech Stock (ALVO) Company Profile

Healthcare (1087)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ALVO's Discussions on Twitter

Compare ALVO vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALVO Alvotech	5.17	1.85B	563.46M	27.92M	-146.33M	0.0964
TAK Takeda Pharmaceutical Co Adr	18.29	58.50B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.73	42.84B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.185	40.68B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.49	30.40B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	499.49	21.36B	3.17B	1.29B	1.01B	27.09

Alvotech Stock (ALVO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-09	Eingeleitet	Barclays	Underweight
2025-11-04	Herabstufung	Deutsche Bank	Buy → Hold
2025-10-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-09-23	Hochstufung	Deutsche Bank	Hold → Buy
2025-02-14	Eingeleitet	UBS	Buy
2024-01-29	Hochstufung	Barclays	Equal Weight → Overweight
2023-10-20	Hochstufung	Citigroup	Sell → Neutral
2023-09-21	Eingeleitet	Barclays	Equal Weight
2022-09-07	Eingeleitet	Morgan Stanley	Equal-Weight
2022-09-06	Herabstufung	Citigroup	Buy → Sell
2022-07-26	Eingeleitet	Citigroup	Buy

Alle ansehen

Alvotech Aktie (ALVO) Neueste Nachrichten

Finanzdaten der Alvotech-Aktie (ALVO)

Alvotech (ALVO)

Alvotech Stock (ALVO) Company Profile

Compare ALVO vs TAK, TEVA, HLN, ZTS, UTHR

Alvotech Stock (ALVO) Upgrades & Downgrades

Alvotech Aktie (ALVO) Neueste Nachrichten

What Is Putting Alvotech Stock in Focus? (NASDAQ:ALVO) - Kalkine Media

Citadel Advisors LLC Makes New $6.38 Million Investment in Alvotech $ALVO - MarketBeat

Understanding the Setup: (ALVO) and Scalable Risk - Stock Traders Daily

Alvotech (ALVO) Is Up 7.5% After FDA Accepts Review Of Key Entyvio Biosimilar AVT80 - simplywall.st

Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars - marketscreener.com

Alvotech (NASDAQ:ALVO) Shares Up 5.4%Here's What Happened - MarketBeat

FDA to review Alvotech (Nasdaq: ALVO) subcutaneous Entyvio biosimilar - Stock Titan

Alvotech Says FDA Accepted Biologics License Application for AVT80 - marketscreener.com

Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations - Yahoo Finance

Alvotech (ALVO) Is Up 11.7% After Lotus Biosimilar Licensing Deal and 2026 Guidance Update – Has The Bull Case Changed? - simplywall.st

Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical - Yahoo Finance

Alvotech (ALVO) Stock Still Trades At A Discount After A 57% Rally - simplywall.st

Alvotech to present at upcoming investor conferences in September - Yahoo Finance

Alvotech (ALVO) On FDA Clearance And Lotus Deal As Undervalued Narrative Gains Ground - simplywall.st

BofA starts bullish Alvotech coverage on biosimilar launch cycle - Investing.com

Why Alvotech (ALVO) Is Up 9.2% After $150 Million Lotus Biosimilar Deal And 2026 Update - Sahm

ALVOTECH ($ALVO) Releases Q2 2026 Earnings - Moomoo

Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal - Dealroom

Alvotech Targets Three U.S. Biosimilar Decisions In Q4 After FDA Manufacturing Inspection Closes - Pulse 2.0

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT) - The Globe and Mail

Teleconferência de Resultados do 2T26 da Alvotech (ALVO): Guidance Reafirmado - TradingKey

Alvotech (NASDAQ:ALVO) Builds Momentum Around Biosimilar Expansion - Kalkine Media

Alvotech 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-08-21 - Seeking Alpha

Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia - Contract Pharma

Alvotech (NASDAQ:ALVO) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m - AllSci

Alvotech (NASDAQ: ALVO) bets on U.S. biosimilars with Lotus - Stock Titan

Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets - marketscreener.com

Alvotech Enters Strategic Licensing and Commercialization Agreement with Lotus Pharmaceutical for AVT34 and AVT87 - Quiver Quantitative

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for ... - Enidnews.com

Alvotech and Lotus sign deal for proposed versions of $6.1B and $5.8B medicines - Stock Titan

Alvotech Q2 2026 Earnings Call Transcript - Sahm

Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk - simplywall.st

Alvotech Files H1 2026 Results and Schedules Business Update Call - The Globe and Mail

Alvotech holds rating despite H1 2026 earnings miss and FDA delays, eyes multiple biosimilar approvals by Q4 2026. - Pluang

Alvotech earnings missed by $0.02, revenue fell short of estimates - Investing.com India

Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts (ALVO) - Seeking Alpha

Alvotech (NASDAQ:ALVO) Trading 6.8% HigherHere's What Happened - MarketBeat

Alvotech Q2 Earnings Call Highlights - MarketBeat

Earnings call transcript: Alvotech misses Q2 2026 estimates as revenue stalls - Investing.com

ALVO: Revenue and margins set to rebound in H2 as supply normalizes and portfolio expands - TradingView

Alvotech Q2 2026 Earnings Call Summary - Yahoo Finance

Alvotech Provides Earnings Guidance for the Full Year 2026 - marketscreener.com

Alvotech 1H Adjusted EBITDA $46.9 M >ALVO - Moomoo

Alvotech (ALVO) reports Q2 loss, beats revenue estimates - FXStreet

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Iceland's Alvotech H1 revenue falls 31% on manufacturing program - TradingView

Alvotech (NASDAQ:ALVO) Releases Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat

Alvotech Q2 Results: EPS Misses Estimate, Sales Fall 39% YoY - scanx.trade

Alvotech H1 Results: Revenue falls 31%, EBITDA down 13% - scanx.trade

Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update - The Manila Times

Finanzdaten der Alvotech-Aktie (ALVO)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ALVO